AndrasHeczeyMD
Pediatric Hematology & Oncology • Houston, TXAssociate professor, Pediatric Hematology & Oncology, Baylor College of Medicine
Dr. Heczey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1102 Bates Ave
Houston, TX 77030Phone+1 832-824-1000
Summary
- Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells. He developed bispecific T cell engagers and chimeric antigen receptors which specifically target several solid tumors (including hepatoblastoma, hepatocellular carcinoma, yolk sac tumors, Wilms tumor, rhabdoid tumors etc) when expressed in T cells.
As the Director of the Liver Tumor Center, Dr. Heczey developed a strategy to target glypican-3 (GPC3) with genetically-engineered T lymphocytes. His team is currently evaluating Interleukin-15 and GPC3-CAR expressing T cells in children with solid tumors.
His ultimate goal is to cure all patients with solid cancers by effectively translating preclinical findings from bench-to-bedside.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2009 - 2012
Children's Hospital Los AngelesResidency, Pediatrics, 2006 - 2009
Semmelweis UniversityClass of 2002
Certifications & Licensure
TX State Medical License 2010 - 2026
CA State Medical License 2009 - 2025
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) Start of enrollment: 2019 Mar 28
- GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma Start of enrollment: 2018 Jan 18
- T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) Start of enrollment: 2020 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors.Aaron B Ross, Kriti Puri, Thomas L Johnson, Lilliam D Correa, Tami D John
Pediatric Blood & Cancer. 2025-04-01 - Response to: Correspondence on "Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen rec...Gengwen Tian, Amy N Courtney, Andras Heczey, Leonid S Metelitsa
Journal for Immunotherapy of Cancer. 2025-03-05 - DRIMS: A Synthetic Biology Platform that Enables Deletion, Replacement, Insertion, Mutagenesis, and Synthesis of DNA.Leidy D Caraballo G, Inci Cevher Zeytin, Purva Rathi, Che-Hsing Li, Ai-Ni Tsao
ACS Synthetic Biology. 2025-02-21
Press Mentions
From Bench to Bedside and Back: CAR T Cells Armed with IL-15 Show Promise in Treating Solid CancersJanuary 28th, 2025
CAR T Cells Armed with IL-15 Show Promise in Treating Solid CancersNovember 27th, 2024- Promising Results for CAR-NKT Cell Therapy Against Neuroblastoma in Phase 1 TrialMay 16th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
